RG100204 is effective in a preclinical model of bacterial sepsis
New ApoGlyx results demonstrate that RG100204 is effective in reducing organ damage in a preclinical model of bacterial sepsis.
There is currently no specific treatment for sepsis, the body’s overreaction to infection that often causes severe organ damage, and death. According to the Global Sepsis Alliance, 47 to 50...READ MORE
Finding elusive aquaporin inhibitors
Read a blog article by Jiqing Hansen on the story behind finding the long elusive aquaporin inhibitors
ApoGlyx patent applications granted in new countries
ApoGlyx has applied for two patents covering Aquaporin-9 inhibitor technology. A first patent has been granted in the USA in 2018, and in 2020 in Australia, China, and Japan. A second patent has also been granted in the USA in August 2020.